PCM
ADCT icon

Pentwater Capital Management’s ADC Therapeutics ADCT Stock Holding History

Pentwater Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,000
Closed -$320K – 341
2020
Q4 		$320K Hold
10,000
– – ﹤0.01% 213
2020
Q3 		$330K Buy
+10,000
New +$433K ﹤0.01% 201

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

Pentwater Capital Management's ADCT Position: Q1 2021 in Review

Pentwater Capital Management sold out of ADC Therapeutics (ADCT) in Q1 2021, closing a stake of 10,000 shares — an estimated $320K sold.

Pentwater Capital Management first reported a position in ADCT in Q3 2020 and held it in 2 quarters. The position peaked at $330K in Q3 2020. 59 funds tracked by Wall St. Rank hold ADCT as of Q1 2021.

  • Pentwater Capital Management reported no remaining ADC Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 10,000 ADC Therapeutics shares in Q1 2021, an estimated $320K.
  • Pentwater Capital Management first reported a position in ADC Therapeutics in Q3 2020 and held it in 2 quarters.
  • Pentwater Capital Management's ADC Therapeutics position peaked at $330K in Q3 2020.
  • 59 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2021.

Based on Pentwater Capital Management's 13F filing for Q1 2021, filed 17 May 2021.